Investigating Late-Onset Pompe Prevalence in Neuromuscular Medicine Academic Practices: The IPaNeMA Study.
Journal
Neurology. Genetics
ISSN: 2376-7839
Titre abrégé: Neurol Genet
Pays: United States
ID NLM: 101671068
Informations de publication
Date de publication:
Dec 2021
Dec 2021
Historique:
received:
16
02
2021
revised:
25
05
2021
accepted:
03
08
2021
entrez:
27
10
2022
pubmed:
28
10
2022
medline:
28
10
2022
Statut:
epublish
Résumé
We investigated the prevalence of late-onset Pompe disease (LOPD) in patients presenting to 13 academic, tertiary neuromuscular practices in the United States and Canada. All successive patients presenting with proximal muscle weakness or isolated hyperCKemia and/or neck muscle weakness to these 13 centers were invited to participate in the study. Whole blood was tested for acid alpha-glucosidase (GAA) assay through the fluorometric method, and all cases with enzyme levels of ≤10 pmoL/punch/h were reflexed to molecular testing for mutations in the GAA gene. Clinical and demographic information was abstracted from their clinical visit and, along with study data, entered into a purpose-built REDCap database, and analyzed at the University of California, Irvine. GAA enzyme assay results were available on 906 of the 921 participants who consented for the study. LOPD was confirmed in 9 participants (1% prevalence). Another 9 (1%) were determined to have pseudodeficiency of GAA, whereas 19 (1.9%) were found to be heterozygous for a pathogenic GAA mutation (carriers). Of the definite LOPD participants, 8 (89%) were Caucasian and were heterozygous for the common leaky (IVS1) splice site mutation in the GAA gene (c -32-13T>G), with a second mutation that was previously confirmed to be pathogenic. The prevalence of LOPD in undiagnosed patients meeting the criteria of proximal muscle weakness, high creatine kinase, and/or neck weakness in academic, tertiary neuromuscular practices in the United States and Canada is estimated to be 1%, with an equal prevalence rate of pseudodeficiency alleles. Clinical trial registration number: NCT02838368.
Sections du résumé
Background and Objectives
UNASSIGNED
We investigated the prevalence of late-onset Pompe disease (LOPD) in patients presenting to 13 academic, tertiary neuromuscular practices in the United States and Canada.
Methods
UNASSIGNED
All successive patients presenting with proximal muscle weakness or isolated hyperCKemia and/or neck muscle weakness to these 13 centers were invited to participate in the study. Whole blood was tested for acid alpha-glucosidase (GAA) assay through the fluorometric method, and all cases with enzyme levels of ≤10 pmoL/punch/h were reflexed to molecular testing for mutations in the GAA gene. Clinical and demographic information was abstracted from their clinical visit and, along with study data, entered into a purpose-built REDCap database, and analyzed at the University of California, Irvine.
Results
UNASSIGNED
GAA enzyme assay results were available on 906 of the 921 participants who consented for the study. LOPD was confirmed in 9 participants (1% prevalence). Another 9 (1%) were determined to have pseudodeficiency of GAA, whereas 19 (1.9%) were found to be heterozygous for a pathogenic GAA mutation (carriers). Of the definite LOPD participants, 8 (89%) were Caucasian and were heterozygous for the common leaky (IVS1) splice site mutation in the GAA gene (c -32-13T>G), with a second mutation that was previously confirmed to be pathogenic.
Discussion
UNASSIGNED
The prevalence of LOPD in undiagnosed patients meeting the criteria of proximal muscle weakness, high creatine kinase, and/or neck weakness in academic, tertiary neuromuscular practices in the United States and Canada is estimated to be 1%, with an equal prevalence rate of pseudodeficiency alleles.
Trial Registration Information
UNASSIGNED
Clinical trial registration number: NCT02838368.
Identifiants
pubmed: 36299500
doi: 10.1212/NXG.0000000000000623
pii: NG2021016977
pmc: PMC9595038
doi:
Banques de données
ClinicalTrials.gov
['NCT02838368']
Types de publication
Journal Article
Langues
eng
Pagination
e623Informations de copyright
Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.
Références
Rare Dis. 2015 Jul 15;3(1):e1068978
pubmed: 26619007
Int J Neonatal Screen. 2020 Feb 07;6(1):9
pubmed: 33073007
J Neurol. 2009 Nov;256(11):1881-90
pubmed: 19588081
Pediatr Neonatol. 2013 Aug;54(4):219-27
pubmed: 23632029
N Engl J Med. 2010 Apr 15;362(15):1396-406
pubmed: 20393176
Neurology. 2016 Jul 5;87(1):71-6
pubmed: 27281536
Int J Neonatal Screen. 2020 Jan 21;6(1):4
pubmed: 33073003
Am J Med Genet A. 2014 Jan;164A(1):54-61
pubmed: 24243590
Muscle Nerve. 2009 Jul;40(1):32-6
pubmed: 19533645
J Neurol Neurosurg Psychiatry. 2016 Jan;87(1):5-11
pubmed: 25783438
Electron Physician. 2017 Jul 25;9(7):4886-4889
pubmed: 28894550
J Neurol. 2018 Jan;265(1):159-164
pubmed: 29181627
Orphanet J Rare Dis. 2017 Nov 17;12(1):173
pubmed: 29149851
Neuromuscul Disord. 2016 Nov;26(11):796-800
pubmed: 27666774
Ann Clin Transl Neurol. 2018 Dec 01;5(12):1574-1587
pubmed: 30564623
BMC Med Genet. 2014 Dec 20;15:141
pubmed: 25526786
Eur J Hum Genet. 1999 Sep;7(6):713-6
pubmed: 10482961
Acta Neurol Scand. 2016 Feb;133(2):131-135
pubmed: 26190396
Neuromuscul Disord. 2017 Jun;27(6):550-556
pubmed: 28433475
Brain. 2005 Mar;128(Pt 3):671-7
pubmed: 15659425
Neuromuscul Disord. 2015 Jul;25(7):548-53
pubmed: 25998610
Neuromuscul Disord. 2014 Nov;24(11):982-5
pubmed: 25047669
Mol Genet Metab. 2015 Apr;114(4):580-3
pubmed: 25752415
Acta Neurol Scand. 2018 Jan;137(1):85-90
pubmed: 28832912
J Pediatr. 2015 Apr;166(4):985-91.e1-2
pubmed: 25466677
Mol Genet Metab. 2013 Nov;110(3):287-9
pubmed: 24011652
Neuromuscul Disord. 2018 Mar;28(3):257-261
pubmed: 29326002
Int J Neonatal Screen. 2020 Feb 14;6(1):11
pubmed: 33073009
Rev Port Pneumol (2006). 2017 Jul - Aug;23(4):208-215
pubmed: 28499810
J Inherit Metab Dis. 2018 Nov;41(6):937-946
pubmed: 30155607
Int J Neonatal Screen. 2018 Jul 18;4(3):24
pubmed: 33072946
Neurology. 2016 Jul 19;87(3):295-8
pubmed: 27170567
Am J Med Genet C Semin Med Genet. 2012 Feb 15;160C(1):40-9
pubmed: 22252923
Muscle Nerve. 2009 Jul;40(1):149-60
pubmed: 19533647